The ABCs of antiphospholipid syndrome
Archives of Rheumatology, cilt.38, sa.2, ss.163-173, 2023 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 38 Sayı: 2
- Basım Tarihi: 2023
- Doi Numarası: 10.46497/archrheumatol.2023.41875
- Dergi Adı: Archives of Rheumatology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.163-173
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Hayır
Özet
Antiphospholipid syndrome (APS) is a thromboinflammatory syndrome characterized by thrombotic, microvascular, obstetric, or non-thrombotic events in the setting of persistent antiphospholipid antibodies (aPL), namely anticardiolipin antibody (aCL), anti-β2 glycoprotein-I antibody (aβ2GPI), and lupus anticoagulant (LA). The diagnosis of APS requires careful assessment of the aPL profile, the clinical phenotype, and additional risk factors. The standard management of aPL-related thrombosis is anticoagulation, which is not effective for microvascular and non-thrombotic events. In parallel to our improved understanding of aPL-related mechanisms, the role of immunosuppression has been increasingly investigated. In this review, we summarize the basic concepts and future perspectives in APS.